EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease

Yuqing Huang, Yi Ning, Zhiwei Chen, Peiran Song, Haotian Tang, Wenhao Shi, Zhipeng Wan, Gege Huang, Qiupei Liu, Yun Chen, Yu Zhou, Yuantong Li und 4 weitere

Molecules · 2024

DOI: 10.3390/molecules29081803 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Yuqing Huang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Peritonitis, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, High-level Innovative Research Institute, Department of Science and Technology of Guangdong Province, Institutes for Drug Discovery and Development, the Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IRAK4 is a critical mediator in NF-κB-regulated inflammatory signaling and has emerged as a promising therapeutic target for the treatment of autoimmune diseases; however, none of its inhibitors have received FDA approval. In this study, we identified a novel small-molecule IRAK4 kinase inhibitor, DW18134, with an IC50 value of 11.2 nM. DW18134 dose-dependently inhibited the phosphorylation of IRAK4 and IKK in primary peritoneal macrophages and RAW264.7 cells, inhibiting the secretion of TNF-α and IL-6 in both cell lines. The in vivo study demonstrated the efficacy of DW18134, significantly attenuating behavioral scores in an LPS-induced peritonitis model. Mechanistically, DW18134 reduced serum TNF-α and IL-6 levels and attenuated inflammatory tissue injury. By directly blocking IRAK4 activation, DW18134 diminished liver macrophage infiltration and the expression of related inflammatory cytokines in peritonitis mice. Additionally, in the DSS-induced colitis model, DW18134 significantly reduced the disease activity index (DAI) and normalized food and water intake and body weight. Furthermore, DW18134 restored intestinal damage and reduced inflammatory cytokine expression in mice by blocking the IRAK4 signaling pathway. Notably, DW18134 protected DSS-threatened intestinal barrier function by upregulating tight junction gene expression. In conclusion, our findings reported a novel IRAK4 inhibitor, DW18134, as a promising candidate for treating inflammatory diseases, including peritonitis and IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1 Receptor-Associated KinasesPeritonitisInflammatory Bowel DiseasesAnimalsMiceRAW 264.7 CellsProtein Kinase InhibitorsDisease Models, AnimalSignal TransductionMacrophages, PeritonealHumansMalePhosphorylationCytokinesNF-kappa BMice, Inbred C57BL

Stichwörter der Autor:innen

IRAK4 inhibitorinflammatory bowel disease (IBD)macrophageperitonitis

Substanzen

Interleukin-1 Receptor-Associated KinasesProtein Kinase InhibitorsIrak4 protein, mouseCytokinesNF-kappa B

Autor:innen und Institutionen

  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
  • College of Pharmacy, Guizhou Medical University, Guiyang 561113, China.
  • Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • University of Chinese Academy of Sciences, Beijing 100049, China.
  • Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Department of Chemical and Environment Engineering, Science and Engineering Building, The University of Nottingham Ningbo China, Ningbo 315100, China.

Förderung

  • National Natural Science Foundation of China
  • High-level Innovative Research Institute, Department of Science and Technology of Guangdong Province
  • Institutes for Drug Discovery and Development, the Chinese Academy of Sciences
  • State Key Laboratory of Drug Research

Zitieren

APA

Huang, Y., Ning, Y., Chen, Z., Song, P., Tang, H., Shi, W., Wan, Z., Huang, G., Liu, Q., Chen, Y., Zhou, Y., Li, Y., Zhan, Z., Ding, J., Duan, W., & Xie, H. (2024). A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease. Molecules. https://doi.org/10.3390/molecules29081803

Vancouver

Huang Y, Ning Y, Chen Z, Song P, Tang H, Shi W, et al. A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease. Molecules. 2024. doi:10.3390/molecules29081803

BibTeX
@article{Huang2024,
  author = {Huang, Yuqing and Ning, Yi and Chen, Zhiwei and Song, Peiran and Tang, Haotian and Shi, Wenhao and Wan, Zhipeng and Huang, Gege and Liu, Qiupei and Chen, Yun and Zhou, Yu and Li, Yuantong and Zhan, Zhengsheng and Ding, Jian and Duan, Wenhu and Xie, Hua},
  title = {A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29081803}
}
Kostenlos starten →